Literature DB >> 27006387

A novel DFP tripeptide motif interacts with the coagulation factor XI apple 2 domain.

Szu S Wong1, Søren Østergaard2, Gareth Hall3, Chan Li3, Philip M Williams3, Henning Stennicke2, Jonas Emsley3.   

Abstract

Factor XI (FXI) is the zymogen of FXIa, which cleaves FIX in the intrinsic pathway of coagulation. FXI is known to exist as a dimer and interacts with multiple proteins via its 4 apple domains in the "saucer section" of the enzyme; however, to date, no complex crystal structure has been described. To investigate protein interactions of FXI, a large random peptide library consisting of 10(6) to 10(7) peptides was screened for FXI binding, which identified a series of FXI binding motifs containing the signature Asp-Phe-Pro (DFP) tripeptide. Motifs containing this core tripeptide were found in diverse proteins, including the known ligand high-molecular-weight kininogen (HK), as well as the extracellular matrix proteins laminin and collagen V. To define the binding site on FXI, we determined the crystal structure of FXI in complex with the HK-derived peptide NPISDFPDT. This revealed the location of the DFP peptide bound to the FXI apple 2 domain, and central to the interaction, the DFP phenylalanine side-chain inserts into a major hydrophobic pocket in the apple 2 domain and the isoleucine occupies a flanking minor pocket. Two further structures of FXI in complex with the laminin-derived peptide EFPDFP and a DFP peptide from the random screen demonstrated binding in the same pocket, although in a slightly different conformation, thus revealing some flexibility in the molecular interactions of the FXI apple 2 domain.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27006387      PMCID: PMC4991086          DOI: 10.1182/blood-2015-10-676122

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Crystal structure of the factor XI zymogen reveals a pathway for transactivation.

Authors:  Evangelos Papagrigoriou; Paul A McEwan; Peter N Walsh; Jonas Emsley
Journal:  Nat Struct Mol Biol       Date:  2006-05-14       Impact factor: 15.369

2.  A new type of synthetic peptide library for identifying ligand-binding activity.

Authors:  K S Lam; S E Salmon; E M Hersh; V J Hruby; W M Kazmierski; R J Knapp
Journal:  Nature       Date:  1991-11-07       Impact factor: 49.962

3.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

4.  Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII.

Authors:  B N Bouma; J H Griffin
Journal:  J Biol Chem       Date:  1977-09-25       Impact factor: 5.157

5.  Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation.

Authors:  Friederike Langhauser; Eva Göb; Peter Kraft; Christian Geis; Joachim Schmitt; Marc Brede; Kerstin Göbel; Xavier Helluy; Mirko Pham; Martin Bendszus; Peter Jakob; Guido Stoll; Sven G Meuth; Bernhard Nieswandt; Keith R McCrae; Christoph Kleinschnitz
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

6.  Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice.

Authors:  X Wang; Q Cheng; L Xu; G Z Feuerstein; M-Y Hsu; P L Smith; D A Seiffert; W A Schumacher; M L Ogletree; D Gailani
Journal:  J Thromb Haemost       Date:  2005-02-23       Impact factor: 5.824

7.  Collagen alpha B chain: increased proportion in human atherosclerosis.

Authors:  A Ooshima
Journal:  Science       Date:  1981-08-07       Impact factor: 47.728

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.

Authors:  R C Wiggins; B N Bouma; C G Cochrane; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  5 in total

Review 1.  An update on factor XI structure and function.

Authors:  Bassem M Mohammed; Anton Matafonov; Ivan Ivanov; Mao-Fu Sun; Qiufang Cheng; S Kent Dickeson; Chan Li; David Sun; Ingrid M Verhamme; Jonas Emsley; David Gailani
Journal:  Thromb Res       Date:  2017-10-10       Impact factor: 3.944

2.  Protease activity in single-chain prekallikrein.

Authors:  Ivan Ivanov; Ingrid M Verhamme; Mao-Fu Sun; Bassem Mohammed; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Kusumam Joseph; Allen P Kaplan; David Gailani
Journal:  Blood       Date:  2020-02-20       Impact factor: 25.476

3.  Structure of the Yeast Cell Wall Integrity Sensor Wsc1 Reveals an Essential Role of Surface-Exposed Aromatic Clusters.

Authors:  Philipp Schöppner; Anne Pia Lutz; Bernard Johannes Lutterbach; Stefan Brückner; Lars-Oliver Essen; Hans-Ulrich Mösch
Journal:  J Fungi (Basel)       Date:  2022-04-08

Review 4.  Cell Receptor and Cofactor Interactions of the Contact Activation System and Factor XI.

Authors:  Monika Pathak; Bubacarr Gibril Kaira; Alexandre Slater; Jonas Emsley
Journal:  Front Med (Lausanne)       Date:  2018-03-21

5.  Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI.

Authors:  Chan Li; Kayleigh M Voos; Monika Pathak; Gareth Hall; Keith R McCrae; Ingrid Dreveny; Renhao Li; Jonas Emsley
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.